Stevanato Group

Stevanato Group to Report First Quarter 2022 Financial Results on May 10, 2022

Retrieved on: 
Wednesday, April 27, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Medical Devices, NYSE, Solution, Biotechnology, Scientist.com (company), Company, Investor relations, Stevanato Group, Group, Engineering, SIX Financial Information, Fine chemical, Online shopping

The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 Central European Time) on Tuesday, May 10, 2022.

Key Points: 
  • The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 Central European Time) on Tuesday, May 10, 2022.
  • Management will refer to a slide presentation during the call, which will be made available on the day of the call.
  • To view the slide presentation, please visit the Financial Results page, under the Financial Information tab of the Company's Investor Relations section of its website.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Stevanato Group Files Amendment No.1 to Its 2021 Annual Report on Form 20‑F/A

Retrieved on: 
Tuesday, April 5, 2022
Finance, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Other Professional Services, Science, Company, Form, Group, Forward-looking statement, NYSE, Biotechnology, SEC, Risk, Environment, Industry, U.S. Securities and Exchange Commission, Goal, Food and Drug Administration Amendments Act of 2007, Solution, Annual report, Terminology, Engineering, Stevanato Group, Risk management

Stevanato Group filed the Form 20-F/A with the SEC on April 5, 2022 ( www.sec.gov ).

Key Points: 
  • Stevanato Group filed the Form 20-F/A with the SEC on April 5, 2022 ( www.sec.gov ).
  • The Form 20-F/A will be available to shareholders and other interested parties at www.stevanatogroup.com .
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.
  • entitled "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2021, as amended, filed with the SEC.

Global Vial Adaptors for Reconstitution Drug Market Research Report 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 31, 2022
Pharmaceutical, Health, Medical Supplies, Adoption, CAGR, BD (company), Geriatrics, Merck Group, Hyco International Inc, Prevalence, Industry, Technology, Agilent Technologies, West Pharmaceutical Services, Awareness, Stevanato Group, Thermo Fisher Scientific, Drug, Retail

The "Global Vial Adaptors for Reconstitution Drug Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vial Adaptors for Reconstitution Drug Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The vial adaptors for reconstitution drug market is poised to grow by $ 460.98 mn during 2022-2026, progressing at a CAGR of 7.57%
    This study identifies the fluctuating prices of raw materials used in vial adaptors manufacturing as one of the prime reasons driving the vial adaptors for reconstitution drug market growth during the next few years.
  • This report on the vial adaptors for reconstitution drug market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The vial adaptors for reconstitution drug market analysis includes the therapeutic area segment and geographic landscape.

Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Retrieved on: 
Thursday, March 17, 2022
Professional Services, Health, Genetics, Finance, Pharmaceutical, Biotechnology, NYSE, Company, Engineering, Solution, Biotechnology, Medtech, EDT, Environment, Group, Stevanato Group, Forward-looking statement, Risk management

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
  • A live audio webcast will be available on the Companys website at www.stevanatogroup.com under the "Investors" section of the website.
  • Forward-looking statements contained in this press release include, but are not limited to, statements about our participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Stevanato Group to Create Manufacturing Hub in China

Retrieved on: 
Thursday, March 10, 2022
Medical Supplies, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Time, Industry, Technology, Company, Workforce, Behavior, Multimedia, Acquisition, Consulate, NYSE, Dual accreditation, Stevanato Group, Group, Solution, Environment, Biotechnology, Engineering, Forward-looking statement, Fine chemical

The Company is expected to employ approximately 270 people in the China hub.

Key Points: 
  • The Company is expected to employ approximately 270 people in the China hub.
  • Beginning construction on our new manufacturing hub is an important milestone for Stevanato Group in a key market, and will allow us to better serve local customers with premium drug containment solutions and machinery supply.
  • On March 10, 2022, the Company hosted a ribbon cutting event to celebrate the new hub at the presence of local Zhangjiagang and ZETDZ authorities, Italian Consulate representatives in China.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Stevanato Group Announces Agreement With BARDA for the Expansion of Vial Production to Create Industrial Base Capabilities for National Defense

Retrieved on: 
Tuesday, March 1, 2022
Science, Public Policy, Government, Other Science, Biotechnology, Pharmaceutical, White House, Federal Government, Medical Supplies, Health, Ownership, Radiation, Development, Biomedical Advanced Research and Development Authority, Human services, Partnership, Government, Growth, Group, Investment, Department, OMPI, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, Office of the Assistant Secretary for Preparedness and Response, Company, Drug development, Environment, NYSE, United States Department of Health and Human Services, Contract, Stevanato Group, Office of Inspector General, U.S. Department of Health and Human Services, American Rescue Plan Act of 2021, Multimedia, Biotechnology, BARDA, FORCE America, Inc., Assistant, Forward-looking statement, Engineering, Solution, Behavior, Army Contracting Command, Time, Pharmaceutical industry, Renewable energy, Risk management

View the full release here: https://www.businesswire.com/news/home/20220301005405/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220301005405/en/
    Under the agreement, Stevanato Group has agreed to expand its planned manufacturing capacity in Fishers, Indiana, for both standard and EZ-Fill vials.
  • BARDAs financing is intended to strengthen domestic capabilities in the U.S. for national defense readiness and preparedness programs for current and future public health emergencies.
  • In addition, Stevanato Group has agreed to provide priority access to designated BARDA vaccine and drug development partners, when necessary.
  • We believe this investment will rapidly accelerate and scale Stevanato Groups capacity in Indiana and further expand our growth in this key strategic market.

Stevanato Group to Report Fourth Quarter Financial Results on March 8, 2022

Retrieved on: 
Friday, February 18, 2022
Other Manufacturing, Research, Medical Devices, Medical Supplies, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, Engineering, Solution, Stevanato Group, Biotechnology, Participation, Fine chemical

For Participants that do not preregister:

Key Points: 
  • For Participants that do not preregister:
    A live broadcast of the conference call will also be available online at the following link: www.incommuk.com/customers/online (access code 156733).
  • An online archive of the broadcast will be available at the website shortly after the live call and will be available through Tuesday, March 22, 2022.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.
  • Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.

Pharmaceutical investments lead 2021 life sciences growth in Indiana

Retrieved on: 
Wednesday, February 2, 2022
Paragon, Curium, Growth, CGMP, Synthetic Genomics (company), RNA transfection, Biotechnology, Unified Diagnostic Services, 3D, Research, Indiana Biosciences Research Institute, Merck Group, Workforce, Printing, Cancer, Radiopharmaceutical, Company, Tech, KOSDAQ, Science, Education, Acquisition, Industry, Stevanato Group, NYSE, Indiana Economic Development Corporation, Multimedia, Solution, Renewable energy, Pharmaceutical industry, Medical imaging, Pfizer

Indiana was the recipient of inbound investment from eight life sciences companies headquartered in six countries: Australia, Brazil, France, Germany, Italy, and South Korea.

Key Points: 
  • Indiana was the recipient of inbound investment from eight life sciences companies headquartered in six countries: Australia, Brazil, France, Germany, Italy, and South Korea.
  • "Indiana's life sciences sector continues to experience significant growth," said Brian Stemme, senior vice president of engagement at BioCrossroads.
  • Major announcements in 2021 included:
    Stevanato Group [NYSE:STVN], an Italian life sciences company, is planning to establish its new U.S. hub in central Indiana.
  • BioCrossroadsinvests capitalandprovidessupport to life sciences businesses, launches new life sciences enterprises ( Indiana Biosciences Research Institute , 16 Tech , Indiana Health Information Exchange ,and OrthoWorx ), expands collaboration and partnerships among Indiana's life science institutions, promotes science education and markets Indiana's life sciences industry.

Stevanato Group Appoints Riccardo Butta as President, Americas

Retrieved on: 
Wednesday, February 2, 2022
Medical Supplies, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, CEO, Forward-looking statement, Behavior, Engineering, Biotechnology, Goal, Group, Environment, Company, Senior, Stevanato Group, Multimedia, Solution, Pharmaceutical industry, Risk management, Flex

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas.

Key Points: 
  • Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas.
  • We are excited to welcome Riccardo Butta to Stevanato Group, said Franco Moro, CEO of Stevanato Group.
  • Riccardo Butta, President, Americas, commented: I look forward to working with this talented leadership team to expand our presence and market share in the Americas, while continuing Stevanato Groups mission to serve its customers through an integrated approach, from design and development through to commercialization.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Stevanato Group Extends Pen Injector Technology Licensing Agreement With Haselmeier

Retrieved on: 
Wednesday, January 26, 2022
Health, Medical Devices, Diabetes, Managed Care, Pharmaceutical, Cardiology, Biotechnology, Arthritis, Automation, Drug development, Group, Diabetes, Patient, Stevanato Group, Engineering, Pain management, Product management, Biotechnology, Multimedia, Cardiovascular disease, Administration, Lists of diseases, Behavior, Obesity, Company, Technology, Degenerative disease, Solution, Environment, Forward-looking statement, Pharmaceutical industry, Fine chemical

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an extension to its licensing agreement with Haselmeier, a company of the medmix group, for its Axis-D pen injector technology.

Key Points: 
  • Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an extension to its licensing agreement with Haselmeier, a company of the medmix group, for its Axis-D pen injector technology.
  • Stevanato Group is focused on delivering an integrated end-to-end product portfolio, supported by its scientific and analytical processes and services.
  • Utilizing the Axis-D pen injector technology, Stevanato Group has developed its Alina variable-dose and fixed-dose pen injector platform compatible with established therapeutic regimens as well as innovative drug therapies related to diabetes care.
  • Adam Stops, Head of Product Management for Drug Delivery Systems at Stevanato Group, added: "The Alina pen injector platform combines ease of use for patients with faster time-to-market access for pharma organizations.